Home
Scholarly Works
Vedolizumab for Moderate to Severely Active...
Conference

Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium

Authors

Dulai PS; Singh S; Narula N; Peerani F; Whitehead DA; Hudesman D; Kane S; Siegel CA; Sands BE; Colombel J-F

Volume

110

Publisher

Wolters Kluwer

Publication Date

October 1, 2015

DOI

10.14309/00000434-201510001-01904

Conference proceedings

The American Journal of Gastroenterology

ISSN

0002-9270

Contact the Experts team